Partial
Mostly Aligned
Patient Risk:
Info
Summary
Only one claim is supported by the provided FDA label content (Ozempic described as semaglutide injection). The remaining claims about NDC identification/formatting and downstream workflow/reimbursement/dispensing effects are not supported by the available label sections provided.
Category Scores
Accurate Statements
Ozempic is the brand name for semaglutide injection.
Label section 11 DESCRIPTION states “OZEMPIC (semaglutide) injection”.
Unsupported Statements
The text “NDC 4 mg/3 mL 00169” is not enough by itself to uniquely identify the exact product listing.
No NDC uniqueness/identification guidance is present in the available label sections.
NDC numbers are formatted differently across segments (10- vs 11-digit NDCs).
No NDC formatting/digit-length information is present in the available label sections.
The same strength can appear under multiple labeler/product configurations.
No labeler/product configuration information is present in the available label sections.
To find the exact match, the full NDC digits exactly as shown on the box label or prescription label are typically needed.
No instructions about using full vs partial NDC digits are present in the available label sections.
The NDC printed on the Ozempic carton can be used to match an NDC to a specific Ozempic presentation.
No carton-to-presentation NDC matching guidance is present in the available label sections.
The NDC printed on the Ozempic carton is often 10 digits.
No digit-length frequency information is present in the available label sections.
The NDC printed on the Ozempic carton can be written in a split format like 5-4-2.
No NDC split-format guidance is present in the available label sections.
The NDC printed on the pharmacy label can be used to match an NDC to a specific Ozempic presentation.
No pharmacy-label NDC matching guidance is present in the available label sections.
Drug pricing/coverage databases can list by NDC.
No discussion of pricing/coverage databases or NDC listing is present in the available label sections.
Drug pricing/coverage databases often require the full NDC, not a partial NDC.
No payer/database processing or full vs partial NDC requirements are present in the available label sections.
Pharmacies and billing systems generally require the complete NDC.
No pharmacy/billing system requirements are present in the available label sections.
A partial NDC identifier can lead to claim rejection in insurance systems.
No insurance claim rejection behavior related to partial NDC is present in the available label sections.
A partial NDC identifier can lead to the wrong product being dispensed.
No dispensing-error assertions tied to partial NDC are present in the available label sections.
A partial NDC identifier can cause delays because the pharmacy has to confirm the correct listing.
No delay/confirmation process related to partial NDC is present in the available label sections.
Contradictions
Important Omissions
Safety Assessment
Potential Patient Risk:
Info
The unsupported claims primarily concern NDC identification and administrative workflow; none of the provided claims are tied to contraindications, boxed warnings, dosing limits, or other core safety content from the label sections provided.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Most NDC-related operational/workflow and formatting claims are not supported by the provided FDA label sections.
Suggested Improvement
Limit claims to label-supported content (e.g., that Ozempic is semaglutide injection) unless additional FDA label sections containing NDC guidance are provided.